[go: up one dir, main page]

DE69535018D1 - Papillomavirus vakzine - Google Patents

Papillomavirus vakzine

Info

Publication number
DE69535018D1
DE69535018D1 DE69535018T DE69535018T DE69535018D1 DE 69535018 D1 DE69535018 D1 DE 69535018D1 DE 69535018 T DE69535018 T DE 69535018T DE 69535018 T DE69535018 T DE 69535018T DE 69535018 D1 DE69535018 D1 DE 69535018D1
Authority
DE
Germany
Prior art keywords
papilloma virus
virus vaccine
proteins
recombinant
papillomavirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69535018T
Other languages
English (en)
Other versions
DE69535018T2 (de
Inventor
Kathrin U Jansen
James C Cook
Hugh A George
Kathryn J Hofmann
Joseph G Joyce
Ernest Dale Lehman
Henry Z Markus
Mark Rosolowsky
Loren D Schultz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE69535018D1 publication Critical patent/DE69535018D1/de
Publication of DE69535018T2 publication Critical patent/DE69535018T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69535018T 1994-05-16 1995-05-15 Papillomavirus vakzine Expired - Lifetime DE69535018T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24279494A 1994-05-16 1994-05-16
US242794 1994-05-16
PCT/US1995/006006 WO1995031532A1 (en) 1994-05-16 1995-05-15 Papillomavirus vaccines

Publications (2)

Publication Number Publication Date
DE69535018D1 true DE69535018D1 (de) 2006-07-06
DE69535018T2 DE69535018T2 (de) 2007-02-15

Family

ID=22916213

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69535018T Expired - Lifetime DE69535018T2 (de) 1994-05-16 1995-05-15 Papillomavirus vakzine

Country Status (24)

Country Link
EP (1) EP0757717B1 (de)
JP (1) JP3863559B2 (de)
CN (1) CN1152935A (de)
AT (1) ATE328068T1 (de)
AU (1) AU693203B2 (de)
BG (1) BG100974A (de)
BR (1) BR9507657A (de)
CA (1) CA2189882C (de)
CZ (1) CZ336696A3 (de)
DE (1) DE69535018T2 (de)
DK (1) DK0757717T3 (de)
ES (1) ES2264126T3 (de)
FI (1) FI119815B (de)
HU (1) HUT76354A (de)
MX (1) MXPA96005662A (de)
NO (1) NO322133B1 (de)
NZ (1) NZ285941A (de)
PL (1) PL183781B1 (de)
PT (1) PT757717E (de)
RO (1) RO117541B1 (de)
RU (1) RU2206608C2 (de)
SI (1) SI0757717T1 (de)
SK (1) SK147696A3 (de)
WO (1) WO1995031532A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153201A (en) * 1993-03-09 2000-11-28 University Of Rochester Oral immunization with papillomavirus virus-like particles
SK35897A3 (en) * 1994-09-22 1998-02-04 Merck & Co Inc Isolated and purified dna molecule, encoding human papillomavirus type 6a, method of expression, pharmaceutical composition, a vaccine and use
AR004464A1 (es) * 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
CA2339034C (en) 1998-08-14 2010-10-12 Merck & Co., Inc. Process for purifying human papillomavirus virus-like particles
PT1126876E (pt) 1998-10-16 2007-04-30 Glaxosmithkline Biolog Sa Sistemas adjuvantes e vacinas
AUPP765398A0 (en) * 1998-12-11 1999-01-14 University Of Queensland, The Treatment of papillomavirus infections
AU764138B2 (en) 1999-02-05 2003-08-14 Merck Sharp & Dohme Corp. Human papilloma virus vaccine formulations
DE10137102A1 (de) 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
NZ535944A (en) 2002-04-30 2007-11-30 Oncolytics Biotech Inc Viral purification method comprising a simple extraction step in which a detergent is directly added to the cell culture, thereafter, cell debris is removed from the extraction mixture by filtration or centrifugation
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
MY140664A (en) * 2003-09-29 2010-01-15 Merck Sharp & Dohme Optimized expression of hpv 45 l1 in yeast
NZ588616A (en) * 2004-09-30 2012-05-25 Bayer Healthcare Llc An apparatus for separating a protein of interest comprising a purification system integrated with a particle removal system
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
CA2664157C (en) 2006-09-29 2015-12-01 Ligocyte Pharmaceuticals, Inc. Norovirus vaccine formulations
CN101617052A (zh) * 2007-01-30 2009-12-30 特兰斯吉恩股份有限公司 用于免疫的乳头瘤病毒e2多肽
CA2683977C (en) 2007-03-14 2017-04-25 Ligocyte Pharmaceuticals, Inc. A method of norovirus virus-like particle purification comprising ion exchange chromatography
AU2008268014B2 (en) 2007-06-26 2013-10-31 Japan As Represented By The Director-General Of National Institute Of Infectious Diseases Vaccine antigen capable of inducing cross-reacting and neutralizing antibody against high-risk-type human papillomavirus
US20100266636A1 (en) 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
KR20100083150A (ko) 2007-09-18 2010-07-21 리고사이트 파머슈티컬즈 인코퍼레이티드 노로바이러스에 대한 보호면역반응을 제공하는 방법
RU2494106C2 (ru) * 2007-11-23 2013-09-27 Шанхай Зеран Биотекнолоджи Ко., Лтд. Гены, кодирующие главный капсидный белок l1 вируса папилломы человека, и их применение
JP5852883B2 (ja) 2008-08-08 2016-02-03 タケダ ワクチン，インコーポレイテッド 交差反応性の増強のための複合カプシドアミノ酸配列を含むウイルス様粒子
PL2444103T3 (pl) * 2009-06-19 2018-05-30 Eyegene Inc. Szczepionka przeciwko rakowi szyjki macicy
CN102234661A (zh) * 2010-04-23 2011-11-09 北京生物制品研究所 人乳头瘤病毒类病毒颗粒的制备方法和外源蛋白表达盒、表达系统
MX373096B (es) 2010-12-02 2020-04-27 Oncolytics Biotech Inc Formulaciones virales líquidas.
DK2646052T3 (en) 2010-12-02 2017-07-17 Oncolytics Biotech Inc LYOPHILIZED VIRAL FORMULATIONS
RU2445357C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 16
RU2445358C1 (ru) * 2011-02-15 2012-03-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей pichia angusta - продуцент капсидного белка l1 вируса папилломы человека типа 18
AU2012248082B2 (en) * 2011-04-29 2015-08-20 Oncolytics Biotech Inc. Methods of purifying viruses using gel permeation chromatography
EA202090699A3 (ru) 2011-07-11 2020-11-30 Такеда Вэксинс, Инк. Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения
JP6228922B2 (ja) * 2011-12-01 2017-11-08 ユニバーシティ・オブ・ケープ・タウンＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｐｅ Ｔｏｗｎ Ｈｐｖキメラ粒子
CN103215302B (zh) * 2012-01-21 2019-01-15 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv18 l1蛋白的方法
CN107916234A (zh) * 2012-03-28 2018-04-17 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv6 l1蛋白的方法
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
CN110484554B (zh) * 2013-04-26 2024-04-16 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv52 l1蛋白的方法
CN110423774A (zh) * 2013-04-26 2019-11-08 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv58 l1蛋白的方法
CN104164374B (zh) * 2013-05-17 2019-10-22 北京安百胜生物科技有限公司 用汉逊酵母表达系统产生hpv31 l1蛋白的方法
CN104673760B (zh) * 2013-11-29 2018-01-02 南京赛威信生物医药有限公司 一种原核细胞表达类病毒颗粒的纯化方法
RU2546240C1 (ru) * 2014-02-13 2015-04-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ ГЛАВНОГО КАПСИДНОГО БЕЛКА L1 ВИРУСА ПАПИЛЛОМЫ ЧЕЛОВЕКА ТИПА 56
RU2546242C1 (ru) * 2014-02-13 2015-04-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ ГЛАВНОГО КАПСИДНОГО БЕЛКА L1 ВИРУСА ПАПИЛЛОМЫ ЧЕЛОВЕКА ТИПА 18
RU2546243C1 (ru) * 2014-02-13 2015-04-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантная вакцина для профилактики папилломавирусной инфекции человека и способ ее получения
RU2546241C1 (ru) * 2014-02-13 2015-04-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" РЕКОМБИНАНТНЫЙ ШТАММ ДРОЖЖЕЙ Hansenula polymorpha - ПРОДУЦЕНТ ГЛАВНОГО КАПСИДНОГО БЕЛКА L1 ВИРУСА ПАПИЛЛОМЫ ЧЕЛОВЕКА ТИПА 16
RU2677336C2 (ru) * 2014-12-26 2019-01-16 Айджин, Инк. Способ получения вирусоподобных частиц папилломавируса человека
WO2017041083A1 (en) * 2015-09-04 2017-03-09 Inventprise, Llc Vlp stabilized vaccine compositions
RU2676160C1 (ru) * 2018-02-14 2018-12-26 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантный штамм дрожжей Hansenula polymorpha - продуцент главного капсидного белка L1 вируса папилломы человека типа 11
RU2681174C1 (ru) * 2018-07-12 2019-03-04 Закрытое акционерное общество научно-производственная компания "Комбиотех" Способ получения рекомбинантной вакцины для профилактики папилломавирусной инфекции человека, рекомбинантная вакцина
MX2022000778A (es) 2019-07-19 2022-02-14 Sinocelltech Ltd Proteina quimerica l1 del virus de papiloma humano.
CN116426396B (zh) * 2023-06-09 2023-09-01 内蒙古工业大学 一株耐硫酸铵酿酒酵母及其筛选方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2586428B1 (fr) * 1985-08-26 1988-11-25 Pasteur Institut Polypeptides et anticorps, caracteristiques du papillomavirus et leurs applications au diagnostic in vitro, a la prevention et/ou la lutte contre des infections a papillomavirus
DE3625257A1 (de) * 1986-07-23 1988-02-04 Behringwerke Ag Expressionsprodukte der menschlichen papillomviren typ 16 und 18, fuer diese proteine spezifische antikoerper und diese antikoerper bzw. entsprechende dna enthaltende diagnostika
ES2267890T3 (es) * 1991-07-19 2007-03-16 The University Of Queensland Segmento polinucleotido de genoma hpv16.
EP1835029A1 (de) * 1992-06-25 2007-09-19 Georgetown University Impfstoffe gegen den Papillomavirus
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
DE4332596A1 (de) * 1993-09-24 1995-03-30 Martin Josef Dr Sapp Monoklonale Antikörper
AUPM566794A0 (en) * 1994-05-17 1994-06-09 University Of Queensland, The Process and product

Also Published As

Publication number Publication date
FI119815B (fi) 2009-03-31
MXPA96005662A (es) 2004-08-19
HUT76354A (en) 1997-08-28
CA2189882A1 (en) 1995-11-23
CA2189882C (en) 2005-09-20
FI964592L (fi) 1996-11-15
PT757717E (pt) 2006-09-29
NZ285941A (en) 1998-05-27
DK0757717T3 (da) 2006-09-25
EP0757717B1 (de) 2006-05-31
AU2549595A (en) 1995-12-05
PL183781B1 (pl) 2002-07-31
BG100974A (en) 1998-04-30
DE69535018T2 (de) 2007-02-15
EP0757717A1 (de) 1997-02-12
SK147696A3 (en) 1997-08-06
ATE328068T1 (de) 2006-06-15
AU693203B2 (en) 1998-06-25
EP0757717A4 (de) 1998-04-15
JP3863559B2 (ja) 2006-12-27
RU2206608C2 (ru) 2003-06-20
SI0757717T1 (sl) 2006-08-31
FI964592A0 (fi) 1996-11-15
CZ336696A3 (en) 1997-07-16
NO964862L (no) 1997-01-16
NO322133B1 (no) 2006-08-21
JPH10500847A (ja) 1998-01-27
ES2264126T3 (es) 2006-12-16
NO964862D0 (no) 1996-11-15
CN1152935A (zh) 1997-06-25
BR9507657A (pt) 1997-09-09
HU9603155D0 (en) 1997-01-28
RO117541B1 (ro) 2002-04-30
PL317234A1 (en) 1997-03-17
WO1995031532A1 (en) 1995-11-23

Similar Documents

Publication Publication Date Title
DE69535018D1 (de) Papillomavirus vakzine
GEP20084431B (en) Papilloma virus vaccine
DK1021547T3 (da) Vaccineformuleringer indeholdende papillomviruskapsomer og fremgangsmåder til anvendelse heraf
NL300324I1 (nl) Op papillomavirus lijkende deeltjes, fusie-eiwitten alsook werkwijze
DE69824013D1 (de) Impfstoff gegen hpv
ATE492289T1 (de) Herstellung von menschlichen papillomavirus hbv- 11 kapsidprotein l1 und virus-ähnliche partikeln
WO1999033868A3 (en) Human papillomavirus vaccine
EA199700281A1 (ru) Молекула днк, кодирующая белок l1 вируса папилломы типа 11 чепловека, экспрессирующий вектор, способ получения очищенных вирусоподобных частиц
MY150893A (en) Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines
HUP9801334A2 (hu) A 18-as típusú humán papillomavírust kódoló DNS
AU8200791A (en) Ehv-4 glycoprotein vaccine
DE69736779D1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
HUP0003511A2 (hu) Hepatitisz-B-vírus polipeptidek
AU1814792A (en) Immunogenic peptides or polypeptides of the bvd virus and related viruses, vaccines incorporating them or expressing them, methods and means of production thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY, N.J., US

R081 Change of applicant/patentee

Ref document number: 757717

Country of ref document: EP

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., 07065-0900 RAHWAY, US

Effective date: 20121213

R082 Change of representative

Ref document number: 757717

Country of ref document: EP

Representative=s name: ABITZ & PARTNER, DE

Effective date: 20121213